Cancer Vaccines: Overall Survival Versus Progression-Free Survival
Monday, April 6, 2015 - 11:20
in Health & Medicine
Therapeutic anti-cancer vaccines developed to treat metastatic disease such as advanced prostate cancer or melanoma don'thave a noticeable effect on the tumor but are linked to a statistically significant increase in patient survival. For that reason, "overall survival" rather than "progression-free survival" should be the gold standard for evaluating the efficacy of cancer vaccines in clinical trials, according to a new editorial in Cancer Biotherapy and Radiopharmaceuticals. read more